Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23139019)

1.

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.

Perez Ruixo JJ, Ma P, Chow AT.

AAPS J. 2013 Jan;15(1):172-82. doi: 10.1208/s12248-012-9424-8. Epub 2012 Nov 10. Review.

2.

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Chen X, Hickling T, Kraynov E, Kuang B, Parng C, Vicini P.

AAPS J. 2013 Oct;15(4):1141-54. doi: 10.1208/s12248-013-9517-z. Epub 2013 Aug 30.

3.

Impact of anti-drug antibodies in preclinical pharmacokinetic assessment.

Thway TM, Magana I, Bautista A, Jawa V, Gu W, Ma M.

AAPS J. 2013 Jul;15(3):856-63. doi: 10.1208/s12248-013-9484-4. Epub 2013 May 8.

4.

A guide to rational dosing of monoclonal antibodies.

Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ.

Clin Pharmacokinet. 2012 Feb 1;51(2):119-35. doi: 10.2165/11596370-000000000-00000.

PMID:
22257150
5.

Review on modeling anti-antibody responses to monoclonal antibodies.

Gómez-Mantilla JD, Trocóniz IF, Parra-Guillén Z, Garrido MJ.

J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):523-36. doi: 10.1007/s10928-014-9367-z. Epub 2014 Jul 16.

PMID:
25027160
6.

Pharmacokinetics/pharmacodynamics model-supported early drug development.

Chen B, Dong JQ, Pan WJ, Ruiz A.

Curr Pharm Biotechnol. 2012 Jun;13(7):1360-75. Review.

PMID:
22201585
7.

Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Luu KT, Kraynov E, Kuang B, Vicini P, Zhong WZ.

AAPS J. 2013 Apr;15(2):551-8. doi: 10.1208/s12248-013-9464-8. Epub 2013 Feb 14. Review.

8.

Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics.

Zhou L, Hoofring SA, Wu Y, Vu T, Ma P, Swanson SJ, Chirmule N, Starcevic M.

AAPS J. 2013 Jan;15(1):30-40. doi: 10.1208/s12248-012-9408-8. Epub 2012 Oct 9.

9.

Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

Gieschke R, Steimer JL.

Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58.

PMID:
11032091
10.

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

Deng R, Jin F, Prabhu S, Iyer S.

Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):141-60. doi: 10.1517/17425255.2012.643868. Epub 2012 Jan 17. Review.

PMID:
22248267
11.
12.

Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Ghobadi C, Johnson TN, Aarabi M, Almond LM, Allabi AC, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A.

Clin Pharmacokinet. 2011 Dec 1;50(12):809-22. doi: 10.2165/11594420-000000000-00000.

PMID:
22087867
13.

Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.

Chaikin P, Rhodes GR, Bruno R, Rohatagi S, Natarajan C.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1428-38. Review.

PMID:
11185663
14.

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.

Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E.

J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.

15.

Facilitation of drug evaluation in children by population methods and modelling.

Tod M, Jullien V, Pons G.

Clin Pharmacokinet. 2008;47(4):231-43. Review.

PMID:
18336053
16.

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H.

Br J Clin Pharmacol. 2011 Aug;72(2):270-81. doi: 10.1111/j.1365-2125.2011.03964.x.

17.

Circumventing immunogenicity in the development of therapeutic antibodies.

Holgate RG, Baker MP.

IDrugs. 2009 Apr;12(4):233-7. Review.

PMID:
19350467
18.

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM.

Trends Biotechnol. 2010 Oct;28(10):509-16. doi: 10.1016/j.tibtech.2010.07.001. Epub 2010 Aug 4. Review.

PMID:
20691488
19.

How modeling and simulation have enhanced decision making in new drug development.

Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL.

J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):185-97. Epub 2005 Nov 7. Review.

PMID:
16283534
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk